$49.36
-2.28 (-4.42%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TEM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 10 observational · 1 with posted results
Held by 12 tracked-famous managers (BAILLIE GIFFORD & CO, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MARSHALL WACE, LLP, +7 more) · FINRA short interest 5.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 7 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic MalignanciesNCT07154823observationalTo assess biomarker landscape in the progression as well as baseline biospecimen samples and correlate with with real-world outcomes across multiple hematologic indications. | — | Recruiting | Other: None - Observational Study | Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL) | 550 | Nov 2034 | ≤ 3,025 d | 2026-07-21 |
| Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast MalignanciesNCT07211178observationalInvasive Disease-Free Survival (iDFS) stratified by MRD status during neoadjuvant, post-surgery landmark, post definitive treatment (surveillance), and long-term follow-up | — | Recruiting | Other: There are no interventions in this observational study. | Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer, Early Stage Breast Cancer | 900 | Dec 2032 | ≤ 2,326 d | 2026-06-12 |
| Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in CancerNCT07756034observationalCompleteness and Yield of Multi-Modal Real-World Data Capture | — | Recruiting | — | Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia, Hematologic Malignancies | 1,000 | Jul 2031 | ≤ 1,807 d | 2026-08-10 |
| GEMINI-NSCLC: NSCLC Biomarker StudyNCT05236114observationalReal-World Disease Free Survival (rwDFS) | — | Recruiting | Other: Observation | Non-Small Cell Lung Cancer | 1,200 | Jun 2029 | ≤ 1,046 d | 2026-02-05 |
| TEMPUS ARIES: A Biobank Registry Platform Study in OncologyNCT06207032observationalChanges in ctDNA from baseline, on-treatment and post-treatment blood samples. | — | Recruiting | — | Cancer | 500 | 2029-06-01 | in 1,017 d | 2026-02-24 |
| Tempus Small Cell Lung Cancer Observational Study (Sculptor)NCT05257551observationalTo determine if tumor tissue transcriptional subtypes can be detected | — | Recruiting | Other: Observation | Small Cell Lung Cancer | 200 | Mar 2029 | ≤ 955 d | 2026-06-15 |
| Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary HypertensionNCT06911632Proportion of participants receiving a new diagnosis of PH within the High risk Device group compared to the High risk Control group.Randomized · Open-label · Diagnostic | Not applicable | Recruiting | Device: ECG-based AI Device - Results Returned to Investigator, ECG-based AI Device - Results Not Returned to Investigator · Procedure: Echocardiogram and Right Heart Catheterization | Pulmonary Hypertension, Interstitial Lung Disease (ILD) | 900 | May 2028 | ≤ 651 d | 2026-08-04 |
| A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)NCT06163534observationalExplore DNA, RNA, immune and other multiomic biomarkers to better understand prognostic or predictive biomarkers and to inform future research for new relevant biomarkers. | — | Recruiting | — | Head and Neck Squamous Cell Carcinoma | 500 | 2028-03-01 | in 560 d | 2026-06-12 |
| Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS AssaysNCT05234177observationalRecurrence-Free Survival | — | Recruiting | Other: Observation | Colorectal Cancer | 300 | Feb 2027 | ≤ 193 d | 2025-05-06 |
| Tempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information | — | Active, not recruiting | Other: Observation | Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer | 1,000 | 2026-10-19 | in 61 d | 2025-05-06 |
| Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR PlatformNCT06099665Establish impact of automated alerts on the hierarchical composite endpoint of valve intervention (VI) or follow-up visit with a multi-disciplinary heart team (MHT).Randomized · Open-label · Health services research | Not applicable | Completed | Behavioral: Automated alert | Aortic Valve Stenosis, Mitral Regurgitation | 2,118 | 2025-12-01actual | — | 2026-03-06 |
| Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart DiseaseNCT05442203Positive-predictive value (PPV) of the AF device at six monthsOpen-label · Diagnostic | Not applicable | Unknown status | Device: Zio Patch Monitor, Echocardiogram | Atrial Fibrillation, Structural Heart Disease | 1,000 | Jul 2025 | — | 2024-07-25 |
| Umbrella Study for Analysis of Data Related to Patients With CancerNCT06018753observationalProvide RWD/E Datasets to Research Collaborators to Support Development | — | Completed | — | Cancer | 77 | 2025-07-01actual | — | 2026-06-29 |
| Niraparib in the Treatment of Patients With Advanced PALB2 Mutated TumorsNCT05169437results2025-10-29Overall Response Rate (ORR) - Independent Central Review (ICR)Open-label · TreatmentStudy Protocol: Full Study Protocol ↗ · Study Protocol: Protocol Clarification Letter ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Recruitment challenges | Drug: Niraparib | Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor, Urologic Cancer, Pancreatic Cancer, Melanoma, Metastatic Cancer, Locally Advanced Solid Tumor, Esophageal Cancer, Endometrial Cancer, Head and Neck Cancer | 22 | 2024-08-06actual | — | 2025-10-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19